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OBJECTIVES: Patient outcomes for esophageal adenocarcinoma (EAC) have not improved despite huge advances in endoscopic
therapy because cancers are being diagnosed late. Barrett’s esophagus (BE) is the primary precursor lesion for EAC, and thus the
non-endoscopic molecular diagnosis of BE can be an important approach to improve EAC outcomes if robust biomarkers for
timely diagnosis are identified. MicroRNAs (miRNAs) are tissue-specific novel biomarkers that regulate gene expression and may
satisfy this requirement.
METHODS: Patients with gastroesophageal reflux disease (GERD) and BE were selected from an ongoing tissue and serum
repository. BE was defined by the presence of intestinal metaplasia. Previously published miRNA sequencing profiles of GERD and
BE patients allowed us to select three miRNAs, miR-192-5p, -215-5p, and -194-5p, for further testing in a discovery cohort and an
independent validation cohort. Receiver operating curves were generated to calculate the diagnostic accuracy of these miRNAs for
BE diagnosis. To test specificity, the miRNA signature was compared with those of the gastric cardia epithelium and the non-
intestinal-type columnar epithelium (another definition of BE). In addition, to gain insights into BE origin (intestinal vs non-
intestinal), global BE miRNA profiles were compared with the published miRNA profiles of other columnar epithelia in the
gastrointestinal tract, that is, normal stomach and small and large intestine.
RESULTS: The discovery cohort included 67 white male patients (40 with GERD and 27 with BE). The validation cohort included 28
patients (19 with GERD and 11 with BE). In the discovery cohort, the sensitivity, specificity and area under the curve (AUC) of the
three mRNAs for BE diagnosis were 92–100%, 94–95%, and 0.96–0.97, respectively. During validation, the sensitivity and specificity
of miRNAs for BE diagnosis were as follows:miR-192-5p, 92% and 94%, AUC 0.94 (0.80–0.99, P= 0.0004);miR-215-5p, 100% and 94%,
AUC 0.98 (0.84–1, P= 0.0004); and miR-194-5p, 91% and 94%, AUC 0.96 (0.80–0.99, P= 0.0001), respectively. The tested miRNAs
identified all BE patients in both the discovery and the validation cohorts. When compared with non intestinal-type columnar and
gastric cardia epithelia, the miRNA signature was specific to the intestinal-type columnar epithelium. Comparisons of BE miRNA
sequencing data to published data sets for the normal stomach, small intestine and large intestine confirmed that two of the three
miRNAs (miR-215-5p and -194-5p) were specific to the intestinal-type epithelium.
CONCLUSIONS: MicroRNAs are highly accurate for detecting intestinal-type BE epithelia and should be tested further for the non-
endoscopic molecular diagnosis of BE.
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INTRODUCTION
Esophageal adenocarcinoma (EAC) is a cancer of significant
importance to public health because of rapidly increasing
incidence1 and poor survival.2 The major determinant of the
outcome of EAC is the stage at diagnosis.2,3 Early-stage
cancer can be treated with endoscopic therapies to achieve
high cure rates.4 Although EAC progresses stepwise from the
premalignant lesion of Barrett’s esophagus (BE), 490% of
cancer cases arise in patients without a prior diagnosis of BE,
which can result in delayed cancer detection.5 Because current
methods have failed to improve the outcomes for EAC, newer
approaches are needed.6 The American Gastroenterological
Association7 and the American College of Gastroenterology8
guidelines suggest an earlier diagnosis of BE as a strategy to
halt the significant increase in the rate of esophageal cancer.
An important yet underappreciated fact is that ~ 70% of EACs
are prevalent cancers that can be detected by index
endoscopy.9 Thus, expedient BE diagnosis will be beneficial.
Currently, upper endoscopy is the standard for BE diagnosis
and is typically recommended for patients with chronic
gastroesophageal reflux disease (GERD).7,8 However, upper
endoscopy is not logistically feasible for testing the 10 million
individuals with GERD who are at risk for BE. Recently,
investigators from England demonstrated the feasibility of
testing BE-specific molecular markers in non-endoscopically
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obtained cytology specimens as a practical alternative for BE
diagnosis.10 This approach could benefit from the establish-
ment of novel markers with high accuracy. MicroRNAs
(miRNAs) are small RNA molecules that regulate gene
expression and have shown promise as highly specific tissue
biomarkers in multiple premalignant and malignant condi-
tions.11–14 In a landmark paper, miRNAs were more specific
than messenger RNA profiles for diagnosis in multiple cancer
types.12 In addition, miRNAs were found to be useful in
determining the developmental lineage of various cancers.12
These data led us to hypothesize that miRNA expression
could accurately discriminate between GERD and BE
epithelia. Previous studies found candidate miRNAs to be
specific for BE epithelium15–19 but did not systematically
evaluate their diagnostic performance. Prior to larger trials to
test the clinical utility of miRNA for BE diagnosis, their
performance characteristics need to be defined to facilitate
study design. We previously sequenced the miRNA tran-
scriptome in patients with GERD and BE to identify miRNAs
associated with BE pathogenesis, and we identified 10
miRNAs that were differentially expressed.20 In this study,
we had two aims: (1) to determine the accuracy of select
candidate miRNAs for differentiating between patients with
GERD and BE, and (2) to gain insights into the tissue of BE
origin (intestinal vs non-intestinal epithelium) based on the
miRNA expression patterns. For aim 1, we compared miRNA
expression in discovery and validation cohorts between
independent patients with GERD and BE to determine their
diagnostic accuracy, and for aim 2, we correlated the miRNA
profiles of BE with the published miRNA profiles of other
columnar epithelia in the gastrointestinal tract, that is, the
normal stomach,21 small intestine,22 and large intestine.22
METHODS
Subject selection, definitions, and histologic evaluation.
Patients with BE and GERD were selected from an ongoing
prospective tissue and serum repository at the Veterans
Affairs Medical Center, Kansas City, MO, USA (clinical trials
#NCT00574327). The protocol was initially approved on 25
April 2005 and has been annually reviewed and renewed by
the local Institutional Review Board. Details of the repository
have been published previously.20 Patients referred for upper
endoscopy were invited to participate and contribute speci-
mens for molecular research related to GERD and BE. All
patients signed an informed consent document prior to
participation.
GERD was defined on the basis of a validated GERD
questionnaire.23 Based on endoscopy, GERD patients were
further subdivided into those with non-erosive reflux disease
(NERD) and erosive esophagitis (EE). The presence of EE
was graded according to the Los Angeles Classification. BE
was defined by the presence of columnar lined esophagus at
least 1 cm in length and the presence of intestinal metaplasia
on the basis of goblet cells. Biopsies were not obtained from
patients with active ulcerations in the BE segment. The
gastroesophageal junction was identified by the top of gastric
folds. BE lengths were determined according to the Prague
criteria.24 Standard-of-care clinical biopsieswere obtained in a
four-quadrant manner every 1–2 cm in all BE patients using
Radial Jaw 4 biopsy forceps (Boston Scientific, Quincy, MA,
USA). Additional research biopsies were obtained every 2 cm
in BE patients. In patients with GERD, only research biopsies
were obtained from the squamous epithelium 1 cm above the
gastroesophageal junction. The gastric cardia biopsies were
provided by Dr Krishnadath of the Academic Medical Center,
Amsterdam, Netherlands under an approved protocol (study
number: MEC 01/288#08.17.1042). Paired gastric cardia
biopsies were obtained for molecular testing and routine
histopathological evaluation within 2 cm below the gastric
folds. All BE biopsies were reviewed by an experienced
gastrointestinal pathologist (SCM) according to the standar-
dized criteria described by Montgomery et al.25 If there was
concern for high-grade dysplasia and/or cancer, the biopsies
were reviewed by a second pathologist. All discrepant
diagnoses were solved by consensus. For this proposal, we
only included BE patients without dysplasia.
The inclusion criteria for the current feasibility study were as
follows:
1. BE lengths longer than 2 cm. We chose this criterion to
include only well-defined BE patients for this pilot study.
2. BE without dysplasia in both clinical and research biopsies.
We excluded patients with dysplasia to minimize variability
in miRNA expression based on the presence of dysplasia.
Cases, controls, and selection of candidate miRNAs.
Cases were defined as patients with BE. The control group
was composed of patients with GERD (without BE). Both the
cases and the controls were selected randomly from the
repository. We chose GERD patients as the control group
because this is the group at the highest risk for BE and
endorsed for BE screening by the American Gastroenter-
ological Association7 and was included as the control group
in previous studies on molecular diagnosis of BE.10,26
To discover miRNAs associated with BE pathogenesis, we
previously sequenced the entire miRNA transcriptome of
GERD and BE patients followed by verification of the
sequencing results by quantitative real-time polymerase chain
reaction (qRT-PCR) in 67 independent patients.20 These 67
patients formed the discovery cohort for the current study—40
with GERD (20 with EE and 20 with NERD) and 27 with BE.20
We identified 10 miRNAs (three up- and seven downregu-
lated) that were differentially expressed between squamous
and intestinal-type columnar epithelia.20 Select miRNAs were
further evaluated for BE diagnosis in the current study. The
miRNA selection criteria were as follows: (a) upregulation in
BE compared with GERD, (b) high expression in BE tissues by
next-generation sequencing and (c) high degree of differential
expression between GERD and BE tissues. We restricted the
analysis to the upregulated miRNAs because for non-
endoscopic molecular methods, upregulated miRNAs are
more likely to be useful for BE.We finally selected the following
miRNAs for this study:miR-192-5p (240 611 reads per million
(RPM) in BE, fold change 7.9 vs GERD), miR-215-5p (69250
RPM in BE, fold change 9.6 vsGERD), andmiR-194-5p (8 209
RPM in BE, fold change 6.5 vs GERD), respectively.
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We first calculated the sensitivity and specificity of the above
miRNAs for BE diagnosis in the initial discovery cohort of 67
patients and then confirmed the results in an independent
validation cohort.
Additional comparisons to test specificity of the BE
miRNA signature. To test specificity, we also tested miR-
192-5p, -215-5p, and -194-5p in two additional epithelia:
Columnar lined epithelium in the distal esophagus but without
intestinal metaplasia (columnar lined esophagus-no IM).
These patients were selected from the aforementioned
repository. All of these patients underwent four-quadrant
standard-of-care clinical biopsies every 1–2 cm. Additional
research biopsies were obtained. Columnar lined esophagus-
no IM patients were defined by the lack of intestinal metaplasia
in both clinical and research biopsies.
Gastric cardia epithelium. Given that esophageal sampling
devices may obtain cells from gastric cardia, we also
evaluated gastric cardia biopsies to test the specificity of
miRNA markers for BE epithelium. Mucous columnar cells
without goblet cells confirmed gastric cardia epithelium in the
H&E staining of biopsies taken adjacent to the research
biopsies.
Quantitative real-time polymerase chain reaction. RNA
isolation was performed by the TRIzol method (Sigma,
St Louis, MO, USA). Quantitative reverse transcription
polymerase chain reactions were performed as previously
described20 by research associate (XH) blinded to the clinical
diagnosis. In brief 50 ng total RNA was reverse-transcribed
using the Universal RT primer system (Exiqon, Denmark) or
stem-loop primers from Applied Biosystems (Grand Island,
NY, USA). An RT-negative control was included in each
reaction. Each RT reaction was then run in triplicate qPCR
reactions, and the average threshold cycle for that sample (if
variation was o0.3 cycles) was used in all subsequent
calculations. If qPCR variation exceeded 0.3 Ct, then the
sample was re-analyzed. Small nucleolar RNAU6B was used
to normalize for RT and RNA quantification differ-
ences. Relative fold changes were determined by the delta
Ct method using the formula 2− dCt (Ct miRNA-Ct RNAU6B).
Calibrator samples were included across all PCR reactions,
and all values were adjusted based on the Ct values for the
calibrator samples across PCR experiments. In two patients,
PCR reactions did not amplify the template for miR-192-5p
and -215-5p in any of the triplicate reactions and were
excluded from the final analysis.
Statistical analysis. Receiver operating curves were gen-
erated to first calculate the sensitivity and specificity of the
above miRNAs for BE diagnosis in the initial discovery cohort
of 67 patients followed by confirmation in an independent
validation cohort. Receiver operating curves with 95% confi-
dence intervals were computed by logistic regression models
using fold changes. Interactions between miRNA panels were
also tested to improve diagnostic accuracy. To test reliability,
bootstrap analysis was performed, drawing 1000 random
samples with replacement, and receiver operating curves
values with 95% confidence intervals were recalculated.27,28
Bootstrapping is a technique used to estimate variance in
studies with small sample sizes by resampling the original
population multiple times and calculating the distribution of
means. BE miRNA profiles were compared with the published
profiles of normal human stomach (n= 5),21 normal mouse
small intestine (n=7),22 and normal mouse large intestine
(n=6),22 which is reasonable because miRNA expression is
highly conserved across species.29 Because the published
studies used different miRBase versions (13.0–18.0), the
analysis was restricted to those miRNA included in all of the
versions. MicroRNA expression (RPM) was log transformed.
Pearson’s correlation coefficients with 95% confidence
intervals were calculated.
RESULTS
The discovery cohort included 40 GERD (20 NERD and 20
EE) and 27 BE patients as described.20 The validation cohort
included 28 white male patients. For validation, GERD was
Figure 1 Receiver operating curves for miRNAs -192-5p, -215-5p, and -194-5p in the discovery cohort. The graphs show a near complete area under the curve for BE
diagnosis for all the three miRNAs.
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defined by the presence of EE. All GERD patients had EE
grades B or higher. The mean age for patients with GERD
(n=17) was 59±7 years and for patients with BE (n= 11)
was 61± 6 years. The average BE length was Prague
C2.7M4.5 cm (range C0-6 M2-9 cm). The characteristics of
GERD and BE patients in the discovery and validation cohorts
are compared in Supplementary Table 1 online.
In the discovery cohort, the sensitivity and specificity of
miRNAs for BE diagnosis were as follows: miR-192-5p, 100
and 95%, P=0.0004; miR-215-5p, 100 and 93%, P=0.0004;
and miR-194-5p, 97 and 92%, P=0.0001) (Figure 1). Boot-
strap analysis did not substantially alter the results (Table 1).
Individual comparisons of the EE and NERD groups with the
BE group revealed a similar accuracy for BE diagnosis
(Table 2 and Supplementary Figure 1). In the validation cohort,
the sensitivity and specificity were as follows:miR-192-5p, 92 and
94%, area under the curve (AUC) 0.94 (0.80–0.99,
P=0.0004); miR-215-5p, 100 and 94%, AUC 0.98 (0.84–1,
P=0.0004); and miR-194-5p, 91 and 94%, AUC 0.96 (0.80–
0.99, P= 0.0001) (Figure 2). Combining miRNAs into panels
did not further improve accuracy in the discovery (AUC 0.97–
0.99) or the validation cohorts (AUC 0.96–0.99).
To test specificity, we compared the miRNA expression of
intestinal-type columnar epithelium that defined BE in the
current study with (a) gastric cardia epithelium (all white
males, aged 61± 4 years) and (b) non intestinal-type columnar
epithelium from columnar lined esophagus-no IM patients (all
white males, aged 59±6 years, columnar lined esophagus
length 1.3±0.5 cm) (Figure 2). We found that miR-192-5p,
-194-5p, and -215-5p effectively distinguished gastric cardia
epithelium and non-intestinal-type columnar epithelium from
intestinal-type columnar epithelium (Figure 2).
Controversy continues regarding the requirement of intest-
inal versus non-intestinal-type columnar epithelium (common-
alities with gastric epithelium) to define BE.30,31 To gain
insights into the origin of BE, we compared the global miRNA
sequencing profiles of BE mucosa20 with the published
miRNA sequencing profiles of other columnar epithelia in the
gastrointestinal tract—normal stomach,21 small intestine22
and large intestine.22 Globally, there was an incremental
reduction in the correlation of BE miRNA expression with
miRNA expression in the stomach, small intestine and large
intestine (r= 0.824r=0.744r=0.68, respectively), with a
gradient in miRNA expression following proximity to the
esophagus (Figure 3). When we compared the three miRNAs
of interest, we found that miR-192-5p was highly expressed
across all the tissue types (440 000 RPM).MicroRNA-215-5p
was highly abundant in BE (69 250 RPM) and was also
abundant in the small and large intestines (450 000 RPM in
both) but was minimally expressed in the stomach (200 RPM).
MicroRNA-194-5p was expressed similarly among BE, small
intestine and large intestine (8209, 5225, and 4256, respec-
tively) but wasminimally expressed in the stomach (178RPM).
Thus,miR-215-5p and -194-5p were specific to intestinal-type
epithelia.
DISCUSSION
We previously profiled miRNA expression in GERD and BE
epithelia to identify the miRNAs with a potential role in BE
pathogenesis.20 The current study focused on the clinical
utility of specific miRNAs for the expedient diagnosis of BE.
For several reasons, non-endoscopic molecular screening of
BE32 with accurate biomarkers is feasible and could become a
novel, effective approach to control the rapidly increasing rates
of EAC. First, BE is the primary premalignant condition that
predisposes patients to EAC and clearly identifies the at risk
population, and second, two-thirds of all EACs are diagnosed
by the index procedure.9 Thus, timely BE diagnosis could have
the added value of EAC detection. Third, database studies
suggest that if there is no BE on the initial endoscopy, it is
unlikely to develop subsequently.33 Therefore, a single test at
an appropriate age may suffice. In well-defined patients, we
found multiple miRNAs, miR-192-5p, -194-5p, 215-5p to have
an excellent accuracy for BE diagnosis in the discovery and
validation cohorts (91–100% sensitivity and 490% specifi-
city). We also found that the BE miRNA signature was specific
to the intestinal-type columnar epithelium compared with the
non-intestinal-type columnar epithelium and gastric cardia
epithelium. The results were similar when NERD and EE
groups were individually compared with BE, which suggests
that miRNA expression is a strong indicator of epithelial type in
the esophagus and is unlikely to be confounded by the
presence of EE in the GERD group. In addition, comparisons
of BE miRNA sequencing data with published data sets of
other columnar epithelia in the gastrointestinal tract confirmed
the specificity of two of the three miRNAs (-215-5p, -194-5p) to
the intestinal-type epithelium. The results of this feasibility
study strongly support the inclusion of miRNAs as candidate
biomarkers in future larger-scale studies for the molecular
Table 1 Bootstrap analysis of the ROC curves in the discovery cohort
miRNA ROC ROC bootstrap
miR-192-5p 0.97 (0.89–1) 0.97 (0.91–1)
miR-215-5p 0.97 (0.90–0.99) 0.98 (0.92–1)
miR-194-5p 0.96 (0.89–0.99) 0.97 (0.91–1)
ROC, receiver operating curve.
Table 2 Performance characteristics of the miRNAs for BE vs EE and NERD
groups












AUC (95% CI) 0.98 (0.89–1.0) 0.95 (0.85–0.99)
BE, Barrett’s esophagus; CI, confidence interval; EE, erosive esophagitis;
NERD, non-erosive reflux disease.
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diagnosis of BE. Our findings can be directly translated to
non-invasive screening by using non-endoscopic cytology
sponges that are highly effective at acquiring cells.10
Combination of highly specific markers with esophageal
sampling techniques that do not require endoscopy can be
applied in the primary care and community settings and will
provide a practical, convenient and accurate method of BE
diagnosis.
Other investigators have evaluated miRNA differences
between squamous and Barrett’s epithelia.15–19 Our results
are consistent with the study by Fassan et al., who found miRs
-192, -215, and -194 to be progressively upregulated along the
spectrum of squamous/gastric metaplasia/intestinal metapla-
sia. We present additional comparisons with normal gastric
cardia and small and large intestinal epithelium, and we
confirmed the signature to be specific for intestinal-type BE. In
additional, miR-192 was associated with Barrett’s metaplasia
in another study.16 The miRNAs described here are different
than the study by Garman et al.18 possibly due to differences
in methodology (microarray vs sequencing). Future studies
should comprehensively compare the multiple miRNAs
identified by various studies. Importantly, none of the studies
quantitatively describe the diagnostic utility of miRNAs for BE,
sometimes due to a lack of independent groups. In the
Figure 2 Scatter plots for miRNAs -192-5p, -215-5p, and -194-5p in the validation cohort. Four different types of epithelia were compared: squamous mucosa from GERD
patients with erosive esophagitis (EE), columnar lined esophagus with and without intestinal metaplasia (CLE-IM and CLE-no IM that represent two definitions of BE) and gastric
cardia epithelium. All miRNAs show nice separation of BE defined by intestinal metaplasia from other epithelia with miRNA-215-5p detecting all BE patients. The solid line
represents median values.
Figure 3 Heatmap displays the correlation coefficients of global miRNA sequencing profiles of BE epithelia compared with those of normal gastric, small intestinal and large
intestinal epithelia. Under 'intestine', the miRNA profiles of the small and the large intestine were combined for analysis. Although there is a gradient in correlation as a function of
the proximity of the organs, global miRNA profiles of various columnar epithelia are quite similar.
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absence of quantitative data, it is difficult to recognize the
clinical utility of miRNA for BE diagnosis. We present
quantitative data on the ability of miRNAs to diagnose BE;
these data are needed to facilitate the design and sample size
calculations of future prospective clinical trials and to move the
field of BEmolecular diagnosis forward. Another application of
our results would be the reduction of diagnostic confusion that
occurs with shorter lengths of BE. Because goblet cell
distribution is patchy and can be missed, especially with
shorter lengths, our results argue that miRNA expression
might be used to molecularly confirm intestinal-type BE.
Further confirmation is needed.
The feasibility of the molecular diagnosis of BE on cytology
specimens was recently demonstrated by testing for Trefoil
Factor 3, with a sensitivity and specificity of 73% and 94%,
respectively for BE longer than 1 cm.10 The investigators used
immunohistochemistry, a widely available technique in clinical
laboratories. Given that miRNAs are disease specific34 and
that the miRNAs tested in the current study identified all BE
patients both in the discovery and validation cohorts and were
specific to intestinal-type columnar epithelium, miR-192-5p,
-215-5p, -194-5p could improve upon these accuracy rates
and should be further validated in cytology specimens. Other
studies that performed genome-wide methylation analysis
showed the methylation signature to discriminate well
between squamous and columnar (BE) epithelia.35 Prospec-
tive trials are needed to compare the accuracy, variability and
reproducibility of miRNA versus methylation signatures for BE
detection. An important question is how these results can be
applied in clinical practice. PCR-based detection has revolu-
tionized the rapid diagnosis ofClostridiumDifficile and is being
used widely.36 We evaluated miRNA expression based on
relative fold changes. However, we envision that future
advancements in PCR technology such as digital PCR37 will
provide an absolute copy number (rather than relative fold
change) for themiRNA of interest, which could then be used to
develop normative values similarly to clinically used laboratory
tests, for example, liver function tests.
Histopathologically, the BE epithelium is comprised of
multiple cell types with resemblance to both gastric and
intestinal epithelia.30 A recent study by Lavery et al. using
histochemical and mitochondrial DNA mutational analysis
argued that Barrett’s glands resemble pyloric-type gastric
glands with intestinal differentiation over time.31 Other data
suggest that the differentiation into non-specialized columnar
metaplasia vs intestinal metaplasia is modulated by interac-
tions between multiple molecular factors, including pSMAD/
CDX2.38 Analysis in the current study showed the global
miRNA profiles of BEmucosa overlapped with those of normal
gastric, small intestinal and large intestinal mucosa. However,
the expression of specific miRNAs such as -215-5p and -194-
5p was restricted to the intestinal epithelium and may be an
important determinant of the epithelial phenotype; further
study is warranted. MicroRNAs -192, -215, -194 coordinately
regulate important targets in cell cycle regulation such as
Smad interacting protein 1, ZEB2,39 and p5340,41 and may
help us better understand the molecular pathways driving the
'intestinalization' of columnar epithelia in BE with a role in BE
development. Other miRNAs may have a role in BE
carcinogenesis. MicroRNAs -221 and -222 were recently
shown to be upregulated in EAC and were activated by FXR, a
ligand for bile acids.42 These miRNAs promoted degradation
of cdx2 that is important for intestinal differentiation and their
inhibition could have a role in management of BE and EAC.
MicroRNAs can be therapeutically modulated relatively easily
with limited toxicity.43 Thus, miRNA-based therapy could have
a role in chemoprevention and cancer treatment in BE and
EAC, respectively.44
Our study has several limitations but made strong and novel
observations. We included patients with GERD as the control
group instead of healthy volunteers. This study design is
clinically relevant because GERD identifies the population at
highest risk for BE, and the American Gastroenterological
Association guidelines recommend that this population
undergo BE screening.7 For practical purposes, molecular
testing for BE may need to begin with patients at the highest
risk for BE, that is, those with GERD, prior to widespread
population testing. Also, our design is consistent with previous
studies on molecular diagnosis of BE, which defined controls
based on the history of reflux.10,26 Multiple questionnaires are
available to define GERD.23,45–47 We used a validated
questionnaire that we have previously used48,49 to define
GERD. This questionnaire has been shown to be reliable on
test-retest procedure with a median k statistic for the symptom
items of 0.71 (interquartile range, 0.63–0.81).23 We included
only well-defined BE patients with BE lengths greater than
2 cm, and thus the results may be different for shorter lengths
of BE. The sample sizes were relatively small, but the intent
was to conduct a feasibility study prior to large-scale studies.
We performed bootstrap analysis to statistically test the impact
of small sample sizes on our results. The narrow distribution of
confidence intervals after bootstrapping underscores the
reliability of our results (Table 1). A comparison of the BE
miRNA signature with the columnar epithelia of multiple
gastrointestinal organs confirmed specificity and is a strength
of the study. Given that the results were compelling and
consistent between discovery and validation cohorts, this
study provides a strong rationale to conduct prospective
studies to confirm these observations in cytology specimens.
In conclusion, the BE miRNA signature has shown signifi-
cant promise and should be evaluated further as a specific
marker for the presence of intestinal-type BE; this signature
has the potential to improve our understanding of BE
pathogenesis.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Current approaches have not improved the outcomes of
esophageal adenocarcinoma (EAC).
✓ Majority of EAC are not preceded by a timely diagnosis of
Barrett’s esophagus (BE).
✓ Non-endoscopic molecular diagnosis of BE is feasible.
WHAT IS NEW HERE
✓ MicroRNA -192-5p, -215-5p, -194-5p are highly accurate for
BE diagnosis.
✓ These miRNAs can differentiate intestinal-type BE from
non-intestinalized BE and gastric cardia epithelium.
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